Seeking Alpha

SA author The GeoTeam argues that SciClone (SCLN) faces risks that should see it trade at...

SA author The GeoTeam argues that SciClone (SCLN) faces risks that should see it trade at $2.65-$3.80. These include: the failure of the firm's Zadaxin drug, its lead product, in multiple Phase III studies for various uses; probable price reductions in China, SciClone's main source of revenue; and an SEC investigation into bribery in the country. Shares -5.4% to $6.50.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)